ClinicalTrials.gg
RecruitingNCT06594640Updated Jun 10, 2026

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

A Phase 1/2 interventional study of Mitoxantrone Hydrochloride Liposome and Rituximab (R) in Diffuse Large B-cell Lymphoma, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2024, registered Sep 2024).
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
41st of 211
108 · median 46
Started
2024
with 6 others
Phase 1/2
25 of 218
1 open now
Primary completion
2026-06
later than 15 of 37 live
Registered
211th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 41st largest by planned enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2024, is one of 25 in phase 1/2, reaches primary completion later than 15 of the 37 other live ones, and was the 211th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma

Read the detailed description

This is an open, multicenter, prospective phase I/II clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with cyclophosphamide, vincristine, prednisone, and rituximab (R-CMOP) in patients with newly diagnosed diffuse large B-cell lymphoma. The study is divided into two parts. The first part uses a 3+3 dose-escalation design, in which mitoxantrone hydrochloride liposome injection in the R-CMOP regimen will be administered at three different doses: 16 mg/m², 18 mg/m², and 20 mg/m², to determine the recommended Phase 2 dose (RP2D). The second part follows a single-arm design to evaluate the efficacy and safety of the R-CMOP regimen, with mitoxantrone hydrochloride liposome injection administered at the RP2D. Each cycle consists of 21 days. A maximum of 6 cycles of therapy are planned.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Mitoxantrone hydrochloride liposome injection
  • Diffuse Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. confirmed newly diagnosed diffuse large B-cell lymphoma;
  3. Patients must have been untreated, including chemotherapy, targeted therapy, immunotherapy, radiotherapy;
  4. There must be at least one per the Lugano2014 criteria;
  5. For lymph lesion, the long axis must be greater than 1.5cm with 18F-deoxyglucose (18FDG) PET-CT positive;
  6. Ann Arbor stages II-IV;
  7. score 0\~2;
  8. Expected survival time ≥3 months;
  9. a.)Patients should meet the following requirements and must not have received treatment with cell growth factors or blood products within 14 days prior to the hematology test: Absolute value of neutrophils ≥ 1.5 × 10\^9/L; ≥ 75 × 10\^9/L; ≥80g/L. For patients with bone marrow involvement of lymphoma, the requirements are adjusted as follows: (ANC) ≥ 1.0 × 10\^9/L; Platelet count ≥ 50 × 10\^9/L; Hemoglobin level ≥ 75 g/L.

    b.) (AST), alanine aminotransferase (ALT) ≤ 2.5 × ; AST and ALT ≤ 5 × ULN for patients with liver involvement. Total ≤1.5 × ULN (≤ 3 × ULN for patients with Gilbert syndrome); c.) ≥ 50 mL/min or serum creatinine ≤ 2× ULN; d.)Coagulation function: or activated partial thromboplastin time≤ 1.5 × ULN, and international normalized ratio ≤ 1.5;

  10. Female patients of childbearing age must have a negative pregnancy test at the time of enrollment within one week. And patients must agree to use an effective method of from the study initiation until at least 12 months after the last treatment;
  11. Able to understand and comply with the study, and voluntarily sign ; -

Exclusion criteria

Exclusion Criteria:

  1. Primary central nervous system DLBCL, Primary testicular large B-cell lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, Lymphomatoid granulomatosis, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, HHV8-positive DLBCL, Primary effusion lymphoma, Intravascular large B-cell lymphoma, B-cell lymphoma unclassifiable between DLBCL and classical Hodgkin lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, and High-grade B-cell lymphoma;
  2. transformed indolent lymphoma ;
  3. Patients with active central nervous system involvement;
  4. History of hematopoietic stem cell transplantation;
  5. Have received prior anti-lymphoma treatment, excluding short-term or low-dose .;
  6. Used any NMPA-approved anticancer herbal medicines or proprietary Chinese medicines within 14 days prior to the first dose;
  7. History of allergy and to the same class and of the experimental drug;
  8. Participating in any other intervention clinical trials within 4 weeks prior to the first dose except for participation in an observational (non-interventional) clinical study or the follow-up phase of an interventional study;
  9. Active bacterial or viral infections requiring systemic or intravenous drug treatment.
  10. History of immunodeficiency, including anti- positive;
  11. Active and C infection (defined as hepatitis B virus surface antigen positive and hepatitis B virus DNA higher than the (ULN); virus antibody positive and hepatitis C virus RNA higher than the Upper limit of normal);
  12. syphilis infection;
  13. Individuals with an underlying medical condition, alcohol or drug abuse or dependence that impedes study drug administration or interferes with interpretation of study drug toxicity and AE, or results in inadequate or reduced adherence to the study;
  14. Patients with interstitial lung disease that requires treatment; 15: A history of severe cardiovascular disease, including but not limited to:

    1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, or second to third-degree atrioventricular (AV) block;
    2. A mean interval longer than 450 ms, based on three 12-lead ECGs taken at rest;
    3. Acute coronary syndrome, congestive heart failure, stroke, or any other Grade 3 or higher cardiovascular event occurring within 6 months prior to the first dose of therapy;
    4. functional class ≥ II or (LVEF)lower than 50%;
    5. Any factors that increase the risk of QTc prolongation or arrhythmias, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or unexplained sudden death in a first-degree relative under the age of 40, or concurrent use of any medications known to prolong the QT interval;
    6. uncontrolled hypertension;

16. History of other malignant tumor within 2 years, except for DLBCL in this trial or resected locally cancer that has been cured (e.g.basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast); 17. No psychological, spiritual potentially hampering compliance with the study protocol and follow-up schedule; 18. Women who are pregnant or breastfeeding; 19. Any other reasons deemed by the investigator to render the participant unsuitable for inclusion in this clinical trial.

-

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    R-CMOP

    R-CMOP regimen includes rituximab (R), cyclophosphamide (C), mitoxantrone hydrochloride liposome injection (M), vincristine (O), and prednisone (P). The regimen will be administered every 3 weeks, for a maximum of 6 cycles.

    Drug: Mitoxantrone Hydrochloride Liposome · Drug: Rituximab (R) · Drug: Cyclophosphamide (CTX) · Drug: Vincristin · Drug: Prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I:Maximum tolerated dose (MTD)

    Maximum tolerated dose (MTD) of liposomal mitoxantrone hydrochloride in R-CMOP

    Time frame: Through the last patient complete his DLT observation, assessed up to 21 days

  2. Phase I: Recommended phaseII dose (RP2D)

    The Recommended Phase II Dose (RP2D) is defined as the optimal dose of liposomal mitoxantrone hydrochloride for use in Phase II trials, as determined by the outcomes of the Phase I study.

    Time frame: Through the last patient complete his DLT observation, assessed up to 21 days

  3. Phase II:Complete remission rate (CRR)

    Response is assessed according to the lugano criteria

    Time frame: up to 2 years

  4. Phase I: Dose limited toxicities (DLTs)

    adverse events defined as DLT events per protocol

    Time frame: Through the last patient complete his DLT observation, assessed up to 21 days

Secondary outcomes

  1. Phase I: The incidence rates of adverse events (AEs)

    AE or severe adverse events (SAE) occur since the first dose of therapy is given

    Time frame: up to 2 years

  2. Phase I: Objective response rate (ORR)

    Response is assessed according to the lugano criteria

    Time frame: up to 2 years

  3. Phase I: Complete remission rate (CRR)

    Response is assessed according to the lugano criteria

    Time frame: up to 2 years

  4. Phase II: Overall response rate (ORR)

    Response is assessed according to the lugano criteria

    Time frame: up to 2 years

  5. Phase II: Partial response rate (PRR)

    Response is assessed according to the lugano criteria

    Time frame: up to 2 years

  6. Phase II: Duration of response (DOR)

    DOR was defined as the time from first complete response or partial response to disease progression or death from any causes.

    Time frame: up to 2 years

  7. Phase II: Progression-free survival (PFS)

    From the date of the first dose of therapy is given until disease progression or death from any cause.

    Time frame: up to 2 years

  8. Phase II: Overall survival (OS)

    From the date of inclusion to date of death, irrespective of cause

    Time frame: up to 2 years

  9. Phase II: Disease-free survival (DFS)

    From the date of achieving a complete response until disease progression or death from any cause.

    Time frame: up to 2 years

  10. Phase II: Event-free survival (EFS)

    From the date of the first dose of therapy is given until disease progression, death , or the initiation of a new treatment regimen.

    Time frame: up to 2 years

  11. Phase II: The incidence rates of adverse events (AEs)

    AE or severe adverse events (SAE) occur since the first dose of therapy is given

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2026, 25 months after the start.

Of 57 non-industry phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 25 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartActual
May 30, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 30, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06594640
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
May 30, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Wei Liu
Contact
liuwei@ihcams.ac.cn
+86-022-23608461
Lugui Qiu, Professor
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Cyclophosphamide

Start the discussion